Call Us: 1.800.873.5297

By

Pfizer Agrees to $400 Million Settlement in Class-Action Securities Lawsuit Involving Investors

The Wall Street Journal reports that Pfizer has agreed to pay $400 million to settle a class-action securities lawsuit alleging that the company illegally marketed several medications causing its investors to lose money, according to a filing with the United States Securities and Exchange Commission (SEC). The securities lawsuit alleged that Pfizer marketed several drugs […]

By

Pradaxa® MDL 2385 Update: Court Orders Establishment of Qualified Settlement Fund

The Honorable Judge David Herndon, who is overseeing the Pradaxa® Multidistrict Litigation, has ordered the establishment of a “qualified settlement fund” and appointed an administrator of the settlement fund. (CMO 82, In re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation, Case No. 12-md-2385, S.D. Ill.) Now that a qualified settlement fund has been established and an […]

By

Merck Canada Warns Against NuvaRing® Use in Certain Women

According to the Toronto Times Colonist, Merck Canada, Inc., the manufacturers of the contraceptive device NuvaRing®, is warning against NuvaRing® use in women who smoke and who are over the age of 35. Merck Canada met with the Health Canada Advisory Committee on July 31, 2014 to inform them of additional restrictions on NuvaRing® use. […]

By

BMJ Investigation Shows Boehringer Ingelheim Withheld Critical Safety Information on Pradaxa®

Roger Denton of Schlichter, Bogard & Denton, LLP reports that the manufacturers of the blood thinning medication Pradaxa® withheld from regulators critical evidence on how monitoring drug plasma levels could have improved the drug’s safety, according to a recent BMJ Investigation. A recent article published in the British Medical Journal (BMJ) on July 23, 2014 […]

By

State of Oregon Settles $4 Million Deceptive Marketing Claims Involving DePuy’s Metal-on-Metal Hip Implants

The Oregonian Newspaper reports that DePuy Orthopaedics Inc. has settled claims with the Oregon Department of Justice (DOJ) involving their metal-on-metal artificial hips over allegations that the manufacturer knowingly marketed the hips that were prone to failure. The devices were designed to accommodate younger hip replacement patients by providing more flexibility and range of motion […]

By

Manufacturer Seeks FDA Approval of Antidote for Blood Thinning Medication, Pradaxa®

According to recent reports, the German manufacturer, Boehringer Ingelheim, is seeking accelerated approval from the U.S. Food and Drug Administration (FDA) of an antidote for its anticlotting medication, Pradaxa®. The antidote, idarucizumab, is a fully-humanized antibody fragment designed to reverse the anticoagulant effects of Pradaxa®. During a Phase I trial, the antibody showed immediate, complete, […]

By

Xarelto® Blood Thinning Medication Causes Uncontrolled Bleeding, New Lawsuit Alleges

According to a recent lawsuit filed in the Philadelphia County Court of Common Pleas (Stuntebeck v. Johnson & Johnson, et al.), the anticoagulant drug, Xarelto® (rivaroxaban), is alleged to cause serious and uncontrolled internal bleeding that might be irreversible, that could result in life-threatening injuries and even death. The anti-clotting medication Xarelto®, which is marketed […]

By

GlaxoSmithKline (GSK) Settles Promotion Claims: $105 Million Settlement

Bloomberg News reports that GlaxoSmithKline (GSK), the U.K.’s largest drug manufacturer, settled claims nationwide alleging the drug manufacturer illegally promoted asthma and antidepressant drugs. The company will contribute $105 million to a settlement fund over claims asserted by California, New York, and more than 40 other states. California will receive the bulk of the settlement […]

By

Roger Denton and Kristine Kraft of Schlichter, Bogard & Denton, LLP Report that the $100 Million NuvaRing Settlement Will Go Forward

Roger Denton and Kristine Kraft of Schlichter, Bogard & Denton, LLP, Co-Lead Counsel in the NuvaRing Multidistrict Litigation, are pleased to announce that the $100 Million global settlement reached in February will go forward as planned. On February 7, 2014, United States District Court Judge Rodney W. Sippel approved a $100 Million settlement in the […]

By

Pradaxa® MDL Update (MDL 2385): $650 Million Settlement Reached in Federal Multidistrict Litigation

The Plaintiffs’ Steering Committee, appointed by The Honorable Chief Judge David R. Herndon to negotiate the settlement on behalf of all plaintiffs in the Pradaxa® MDL, and Boehringer Ingelheim Pharmaceuticals, Inc. (and affiliates) have negotiated a settlement program in the amount of $650 Million to resolve approximately 4,000 Pradaxa® claims. Roger C. Denton of Schlichter, […]

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.